The agreement includes a non-exclusive license of certain intellectual property, with all AI-related developments owned exclusively by Oncotelic. The joint development will involve cost-sharing and milestone payments based on acceptance criteria, with revenue-sharing terms to be negotiated in a separate commercialization agreement. Both parties are committed to ensuring that the product meets stringent GMP standards, which are critical for regulatory compliance in the pharmaceutical industry.
Dr. Vuong Trieu, CEO of Oncotelic, emphasized the significance of this partnership, stating that it represents a major step in bridging AI and automation within pharmaceutical environments. The collaboration is expected to reduce human intervention, minimize contamination risks, and enhance process consistency through intelligent automation. Ried Floco, President of TechForce, highlighted the potential of combining advanced AI with specialized robotics to scale solutions for real-world applications.
This partnership positions Oncotelic to address the growing demand for intelligent, scalable, and compliant solutions in pharmaceutical manufacturing, particularly as regulatory scrutiny intensifies. The integrated platform is designed to automate critical workflows, ensuring real-time monitoring and compliance, which are essential in today's manufacturing landscape.
